In short
Clinical trials investigating ROTAVIRUS SEROTYPE P1[8] HUMAN-BOVINE ROTAVIRUS REASSORTANTS (LIVE) PRODUCED ON VERO CELLS are designed to study safety and immune response in young children. The trial data provided here focus on healthy infants, toddlers, and children, and measure both side effects and how well the vaccines trigger antibodies.
Key points
- Clinical trial data for ROTAVIRUS SEROTYPE P1[8] HUMAN-BOVINE ROTAVIRUS REASSORTANTS (LIVE) PRODUCED ON VERO CELLS focus on meningococcal immunization in healthy infants, toddlers, and children. The main study is a Phase 2 trial that looks at safety and immune response. Researchers measure side effects such as immediate reactions, injection site reactions, systemic reactions, and serious adverse events. They also measure antibody levels and seroresponse against meningococcal groups A, C, W, Y, and B. The trial is authorised and includes 750 participants.
Trial overview
The provided trial data describe a Phase 2 interventional study of meningococcal immunization in healthy children, toddlers, and infants. The trial is authorised and plans to enroll 750 participants.
The brief summary says the main goal is to describe the safety profile of the MenPenta vaccine formulations in healthy children, toddlers, and infants. It also aims to describe the immune response after vaccination at different time points.
Who can participate
The study population includes healthy infants, toddlers, and children. The brief summary specifically mentions infants vaccinated at about 4 months of age and again at 12 to 15 months of age.
Children and toddlers are also included in the immune response assessment at each time point. The trial data do not describe illness-based inclusion criteria beyond the condition of meningococcal immunization.
What is being measured
The primary outcomes include unsolicited immediate adverse events, solicited injection site reactions, systemic reactions, unsolicited adverse events, and serious adverse events. In simple terms, the study checks both common and more serious safety problems after vaccination.
The study also measures immune response using hSBA, which is a blood test that shows whether antibodies can help kill bacteria. The outcomes include antibody titers, seroresponse, geometric mean titers, and the percentage of participants with antibody levels at or above the lower limit of quantification.
These immune measures are tracked for meningococcal serogroups A, C, W, Y, and B. The data also mention reference MenB strains, which are bacterial strains used for comparison in the test.
Trial phase and status
The study is listed as Phase 2. Phase 2 studies usually look at safety and how the immune system responds in a larger group than early-stage trials.
The status is Authorised. This means the study has official approval in the source data provided.
Study groups and vaccines
The intervention list includes several vaccines, such as MenPenta SD, MenPenta fHD, MenQuadfi, Nimenrix, Bexsero, Prevenar 13, Hexyon, and RotaTeq. The source data present these as comparators or related vaccines used in the study design.
The brief summary says the study compares MenPenta vaccine formulations with comparator vaccines in infants, children, and toddlers. The main focus is not on treating illness, but on comparing safety and immune response across study groups.
How results are assessed
For infants, the immune response is measured before vaccination and 30 days after the second dose, and again after the third dose given at 12 to 15 months of age. For children and toddlers, the study measures hSBA antibody levels and seroresponse at each time point described in the source data.
The trial also reports geometric mean titers, which are average antibody levels calculated in a special way that reduces the effect of very high values. It measures how many participants reach specific antibody thresholds, such as 1:4 or 1:8 for MenB reference strains, and whether antibody levels are above the lower limit of quantification.
Overall, the study is built to show whether the vaccine formulations are safe and whether they produce a measurable immune response in young children.